Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth (Status and Outlook) 2025-2031
According to this study, the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market size will reach US$ million by 2031.
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Forecast” looks at past sales and reviews total world Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales for 2025 through 2031. With Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alpha-1 Antitrypsin Deficiency Augmentation Therapy industry.
This Insight Report provides a comprehensive analysis of the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Alpha-1 Antitrypsin Deficiency Augmentation Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alpha-1 Antitrypsin Deficiency Augmentation Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Alpha-1 Antitrypsin Deficiency Augmentation Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Forecast” looks at past sales and reviews total world Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales for 2025 through 2031. With Alpha-1 Antitrypsin Deficiency Augmentation Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alpha-1 Antitrypsin Deficiency Augmentation Therapy industry.
This Insight Report provides a comprehensive analysis of the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Alpha-1 Antitrypsin Deficiency Augmentation Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alpha-1 Antitrypsin Deficiency Augmentation Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Alpha-1 Antitrypsin Deficiency Augmentation Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Glassia
- Aralast NP
- Prolastin C
- Others
- Hospitals
- Specialty Clinics
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Grifols
- CSL
- Baxter
- Kamada
- Takeda
- Abeona
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
2.1.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Country/Region (2020, 2024 & 2031)
2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Type
2.2.1 Glassia
2.2.2 Aralast NP
2.2.3 Prolastin C
2.2.4 Others
2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
2.3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
2.4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
2.5.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
3 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY MARKET SIZE BY PLAYER
3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Player
3.1.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Player (2020-2025)
3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Player (2020-2025)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY BY REGION
4.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
4.4 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
4.5 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
4.6 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
5.2 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
5.3 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025)
6.2 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
6.3 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
7.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Region (2020-2025)
8.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
8.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY MARKET FORECAST
10.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.1.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.1.2 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.1.3 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.1.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.1.5 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Country (2026-2031)
10.2.1 United States Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2.2 Canada Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2.3 Mexico Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2.4 Brazil Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.3.1 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast
10.3.2 Japan Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.3 Korea Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.4 Southeast Asia Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.5 India Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.6 Australia Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Country (2026-2031)
10.4.1 Germany Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.2 France Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.3 UK Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.4 Italy Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.5 Russia Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.5.1 Egypt Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5.2 South Africa Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5.3 Israel Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5.4 Turkey Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.6 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Type (2026-2031)
10.7 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Grifols
11.1.1 Grifols Company Information
11.1.2 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Grifols Main Business Overview
11.1.5 Grifols Latest Developments
11.2 CSL
11.2.1 CSL Company Information
11.2.2 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 CSL Main Business Overview
11.2.5 CSL Latest Developments
11.3 Baxter
11.3.1 Baxter Company Information
11.3.2 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Baxter Main Business Overview
11.3.5 Baxter Latest Developments
11.4 Kamada
11.4.1 Kamada Company Information
11.4.2 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Kamada Main Business Overview
11.4.5 Kamada Latest Developments
11.5 Takeda
11.5.1 Takeda Company Information
11.5.2 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Takeda Main Business Overview
11.5.5 Takeda Latest Developments
11.6 Abeona
11.6.1 Abeona Company Information
11.6.2 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Abeona Main Business Overview
11.6.5 Abeona Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
2.1.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Country/Region (2020, 2024 & 2031)
2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Type
2.2.1 Glassia
2.2.2 Aralast NP
2.2.3 Prolastin C
2.2.4 Others
2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
2.3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
2.4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
2.5.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
3 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY MARKET SIZE BY PLAYER
3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Player
3.1.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Player (2020-2025)
3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Player (2020-2025)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY BY REGION
4.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
4.4 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
4.5 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
4.6 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
5.2 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
5.3 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025)
6.2 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
6.3 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
7.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Region (2020-2025)
8.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025)
8.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY MARKET FORECAST
10.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.1.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.1.2 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.1.3 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.1.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.1.5 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2 Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Country (2026-2031)
10.2.1 United States Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2.2 Canada Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2.3 Mexico Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.2.4 Brazil Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3 APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.3.1 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast
10.3.2 Japan Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.3 Korea Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.4 Southeast Asia Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.5 India Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.3.6 Australia Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Country (2026-2031)
10.4.1 Germany Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.2 France Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.3 UK Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.4 Italy Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.4.5 Russia Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Region (2026-2031)
10.5.1 Egypt Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5.2 South Africa Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5.3 Israel Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.5.4 Turkey Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
10.6 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Type (2026-2031)
10.7 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Grifols
11.1.1 Grifols Company Information
11.1.2 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Grifols Main Business Overview
11.1.5 Grifols Latest Developments
11.2 CSL
11.2.1 CSL Company Information
11.2.2 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 CSL Main Business Overview
11.2.5 CSL Latest Developments
11.3 Baxter
11.3.1 Baxter Company Information
11.3.2 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Baxter Main Business Overview
11.3.5 Baxter Latest Developments
11.4 Kamada
11.4.1 Kamada Company Information
11.4.2 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Kamada Main Business Overview
11.4.5 Kamada Latest Developments
11.5 Takeda
11.5.1 Takeda Company Information
11.5.2 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Takeda Main Business Overview
11.5.5 Takeda Latest Developments
11.6 Abeona
11.6.1 Abeona Company Information
11.6.2 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
11.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Abeona Main Business Overview
11.6.5 Abeona Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Glassia
Table 4. Major Players of Aralast NP
Table 5. Major Players of Prolastin C
Table 6. Major Players of Others
Table 7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Table 10. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Table 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Player (2020-2025)
Table 15. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Products Offered
Table 16. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Table 21. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Country (2020-2025)
Table 25. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Table 27. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Table 29. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Table 31. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Country (2020-2025)
Table 35. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
Table 41. Key Market Challenges & Risks of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
Table 42. Key Industry Trends of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
Table 43. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. Grifols Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 48. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 49. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. Grifols Main Business
Table 51. Grifols Latest Developments
Table 52. CSL Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 53. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 54. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. CSL Main Business
Table 56. CSL Latest Developments
Table 57. Baxter Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 58. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 59. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Baxter Main Business
Table 61. Baxter Latest Developments
Table 62. Kamada Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 63. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 64. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. Kamada Main Business
Table 66. Kamada Latest Developments
Table 67. Takeda Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 68. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 69. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Takeda Main Business
Table 71. Takeda Latest Developments
Table 72. Abeona Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 73. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 74. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Abeona Main Business
Table 76. Abeona Latest Developments
Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Glassia
Table 4. Major Players of Aralast NP
Table 5. Major Players of Prolastin C
Table 6. Major Players of Others
Table 7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Table 10. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Table 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Player (2020-2025)
Table 15. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Products Offered
Table 16. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Table 21. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Country (2020-2025)
Table 25. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Table 27. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Table 29. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Table 31. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Country (2020-2025)
Table 35. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
Table 41. Key Market Challenges & Risks of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
Table 42. Key Industry Trends of Alpha-1 Antitrypsin Deficiency Augmentation Therapy
Table 43. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. Grifols Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 48. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 49. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. Grifols Main Business
Table 51. Grifols Latest Developments
Table 52. CSL Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 53. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 54. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. CSL Main Business
Table 56. CSL Latest Developments
Table 57. Baxter Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 58. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 59. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Baxter Main Business
Table 61. Baxter Latest Developments
Table 62. Kamada Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 63. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 64. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. Kamada Main Business
Table 66. Kamada Latest Developments
Table 67. Takeda Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 68. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 69. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Takeda Main Business
Table 71. Takeda Latest Developments
Table 72. Abeona Details, Company Type, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Area Served and Its Competitors
Table 73. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offered
Table 74. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 75. Abeona Main Business
Table 76. Abeona Latest Developments
LIST OF FIGURES
Figure 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Country/Region (2024)
Figure 8. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type in 2024
Figure 10. Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Hospitals
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Hospitals (2020-2025) & ($ millions)
Figure 12. Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Specialty Clinics
Figure 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Specialty Clinics (2020-2025) & ($ millions)
Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application in 2024
Figure 15. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Player in 2024
Figure 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Figure 17. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 18. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 19. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 20. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 21. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Value Market Share by Country in 2024
Figure 22. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 23. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 24. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 25. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 26. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region in 2024
Figure 27. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Figure 28. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Figure 29. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 30. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 31. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 32. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 33. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 34. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 35. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Country in 2024
Figure 36. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Figure 37. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Figure 38. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 39. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 40. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 41. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 42. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 43. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Figure 44. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Figure 45. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Figure 46. Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 47. South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 48. Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 49. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 50. GCC Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 51. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 52. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 53. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 54. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 55. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 56. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 57. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 58. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 59. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 60. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 61. Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 62. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 63. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 64. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 65. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 66. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 67. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 68. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 69. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 70. Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 71. South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 72. Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 73. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 74. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share Forecast by Type (2026-2031)
Figure 75. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share Forecast by Application (2026-2031)
Figure 76. GCC Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Country/Region (2024)
Figure 8. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type in 2024
Figure 10. Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Hospitals
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Hospitals (2020-2025) & ($ millions)
Figure 12. Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Specialty Clinics
Figure 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Specialty Clinics (2020-2025) & ($ millions)
Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application in 2024
Figure 15. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Player in 2024
Figure 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Figure 17. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 18. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 19. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 20. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2020-2025 ($ millions)
Figure 21. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Value Market Share by Country in 2024
Figure 22. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 23. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 24. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 25. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 26. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region in 2024
Figure 27. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Figure 28. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Figure 29. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 30. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 31. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 32. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 33. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 34. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 35. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Country in 2024
Figure 36. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Figure 37. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Figure 38. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 39. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 40. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 41. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 42. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 43. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Region (2020-2025)
Figure 44. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Type (2020-2025)
Figure 45. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share by Application (2020-2025)
Figure 46. Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 47. South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 48. Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 49. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 50. GCC Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2020-2025 ($ millions)
Figure 51. Americas Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 52. APAC Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 53. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 54. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 55. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 56. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 57. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 58. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 59. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 60. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 61. Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 62. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 63. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 64. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 65. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 66. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 67. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 68. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 69. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 70. Egypt Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 71. South Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 72. Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 73. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
Figure 74. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share Forecast by Type (2026-2031)
Figure 75. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Market Share Forecast by Application (2026-2031)
Figure 76. GCC Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size 2026-2031 ($ millions)
More Publications
Global Alpha 1 Antitrypsin Deficiency Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032
US$ 3,480.00
January 2026
117 pages
